Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

737.71 -19.02 (-2.51%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

49 50 Next >

Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly

March 27, 2026

INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing...

Via MarketMinute

AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results

March 27, 2026

AstraZeneca (NASDAQ: AZN) shares climbed 2.7% in early trading today, March 27, 2026, following the release of highly anticipated Phase 3 clinical trial results for its latest respiratory blockbuster...

Via MarketMinute

Topics Intellectual Property

Is Regeneron a Multimillionaire-Maker Stock? ↗

March 27, 2026

It's an extremely high bar for any company.

Via The Motley Fool

Topics Intellectual Property

Regeneron Stock Slips Premarket Even After Wall Street Lifts Targets On Strong Q4 — What’s Weighing On The Stock? ↗

February 02, 2026

Via Stocktwits

Regeneron Pharmaceuticals (NASDAQ:REGN) Reports Q4 2025 Earnings Beat Amid Product Transition ↗

January 30, 2026

Via Chartmill

Topics Earnings

Kodiak Sciences Surges 19% as Phase 3 GLOW2 Trial Delivers Vital Win for Diabetic Retinopathy Treatment

March 26, 2026

On March 26, 2026, Kodiak Sciences (Nasdaq: KOD) saw its shares ignite, surging 19% in heavy trading following the announcement of overwhelmingly positive topline results from its Phase 3 GLOW2 study....

Via MarketMinute

The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH

March 26, 2026

On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)...

Via Finterra

Topics Economy Initial Public Offering

This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗

March 20, 2026

This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.

Via The Motley Fool

Is Eli Lilly's Weight Loss Empire in Trouble? ↗

March 13, 2026

It won't be easy to knock the company off its pedestal.

Via The Motley Fool

3 Profitable Stocks We Think Twice About

March 13, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making ↗

March 12, 2026

Regeneron's science and its Dupixent revenue are paving the way for it to further expand its portfolio.

Via The Motley Fool

Topics Earnings

2 Underrated Weight Loss Stocks to Buy Now ↗

March 08, 2026

These companies have a lot more to offer than their prospects in the weight loss market.

Via The Motley Fool

Topics Intellectual Property

1 Nasdaq 100 Stock to Consider Right Now and 2 We Brush Off

March 05, 2026

While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some are dealing with declining dema...

Via StockStory

2 Biotech Giants to Buy in 2026 ↗

March 05, 2026

Both of these players are leaders in their fields.

Via The Motley Fool

Topics Intellectual Property

2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years ↗

February 24, 2026

The pharmaceutical specialist has had strong momentum over the past six months, and that could continue for a while.

Via The Motley Fool

Topics Intellectual Property

1 No-Brainer Biotech Stock To Buy Today and Never Sell ↗

February 21, 2026

This player's pipeline should keep growth going over the long run.

Via The Motley Fool

Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom

February 16, 2026

In a move that could reshape the multi-billion-dollar retinal disease market, French pharmaceutical giant Sanofi (NASDAQ: SNY) has reportedly returned to the negotiating table with a significantly...

Via MarketMinute

Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data

February 16, 2026

The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in...

Via MarketMinute

1 Healthcare Stock Worth Your Attention and 2 Facing Challenges

February 12, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only...

Via StockStory

Topics Stocks

The Great Reversal: Tariffs Ignite Goods Inflation as Services Cool in Latest PCE Data

February 06, 2026

The latest Personal Consumption Expenditures (PCE) price index data has revealed a significant shift in the U.S. inflationary landscape, presenting a complex puzzle for the Federal Reserve. As of early...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

Regeneron (REGN) Q1 2025 Earnings Call Transcript ↗

February 05, 2026

Regeneron (REGN) Q1 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings Supply Chain

Regeneron (REGN) Q2 2025 Earnings Call Transcript ↗

February 05, 2026

Regeneron (REGN) Q2 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Regeneron (REGN) Q4 2024 Earnings Call Transcript ↗

February 05, 2026

Regeneron (REGN) Q4 2024 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Regeneron (REGN) Q3 2024 Earnings Call Transcript ↗

February 05, 2026

Regeneron (REGN) Q3 2024 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

This $24 Million Buy Amid a 45% Stock Drop Signals Conviction in a High-Margin Data Business ↗

January 30, 2026

FactSet delivers integrated financial data and analytics to institutional clients, supporting investment decisions worldwide.

Via The Motley Fool

Regeneron (REGN) Q4 2025 Earnings Call Transcript ↗

January 30, 2026

Regeneron (REGN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

These S&P500 stocks that are showing activity before the opening bell on Friday. ↗

January 30, 2026

Via Chartmill

Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock ↗

January 30, 2026

Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data.

Via Stocktwits

Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025

January 30, 2026

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales up 2.5% year on year to $3.88 billion. Its non-GAAP profit of $11.44 per share was...

Via StockStory

Earnings To Watch: Regeneron (REGN) Reports Q4 Results Tomorrow

January 28, 2026

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

49 50 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.